Find more information about Teva in your location, or contact a local representative on our local sites
North America
International Markets
North America
Toggle North America
International Markets
Toggle International Markets
Europe
Toggle Europe
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
- Study Title
- Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
- Teva Identifier
- TVP-1012/PM103
- ClinicalTrials.gov Identifier
- NCT01049984
- Study Status
- Completed
- Trial Condition(s)
- Parkinson's Disease
- Interventions
- Drug: Rasagiline | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age Range
- 30 Years and older
- Trial Duration
- 12/01/2009 - 10/01/2012
- Phase
- Phase 4
